Comparative Pharmacology
Head-to-head clinical analysis: EXTENDED PHENYTOIN SODIUM versus VALRELEASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXTENDED PHENYTOIN SODIUM versus VALRELEASE.
EXTENDED PHENYTOIN SODIUM vs VALRELEASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenytoin stabilizes neuronal membranes by promoting sodium channel inactivation, reducing repetitive firing of action potentials, and decreasing synaptic transmission.
Increases GABAergic transmission by inhibiting GABA transaminase and blocking voltage-gated sodium channels.
Oral: 100 mg three times daily; intravenous: 10-20 mg/kg loading dose at a maximum rate of 50 mg/min, then 100 mg every 6-8 hours maintenance.
500 mg orally twice daily, extended-release formulation. Maximum dose: 2000 mg/day.
None Documented
None Documented
22–32 hours (mean 24 hours) in adults, dose-dependent due to saturable metabolism; may exceed 60 hours at high concentrations.
Terminal elimination half-life is 6-16 hours (mean 10.6 h) in adults; shorter at 4-12 h in children due to enhanced clearance; prolonged to 12-18 h in hepatic impairment or elderly. Clinical context: Once-daily dosing requires extended-release formulation (Valrelease) to maintain trough levels.
Primarily hepatic metabolism (CYP2C9/CYP2C19), with <5% excreted unchanged renally. Fecal excretion accounts for minor elimination.
Renal: 70-80% as metabolites (valproic acid glucuronide, 3-oxo-valproate, 2-en-valproate) and <3% unchanged. Hepatic: 15-20% via bile into feces. Other: 1-3% exhaled as CO2.
Category D/X
Category C
Anticonvulsant
Anticonvulsant